Edition:
India

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

2,973.50GBp
21 Feb 2018
Change (% chg)

-99.00 (-3.22%)
Prev Close
3,072.50
Open
3,006.50
Day's High
3,030.50
Day's Low
2,940.50
Volume
2,026,617
Avg. Vol
3,197,594
52-wk High
5,067.00
52-wk Low
2,940.50

Latest Key Developments (Source: Significant Developments)

AB Biosciences And Shire Enter Into Agreement
Tuesday, 30 Jan 2018 

Jan 30 (Reuters) - Shire Plc ::AB BIOSCIENCES AND SHIRE ENTER INTO AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF AB BIOSCIENCES' PRIM PROGRAM.SHIRE PLC - NO FURTHER TERMS OF AGREEMENT WERE DISCLOSED.SHIRE PLC - ‍AB BIOSCIENCES TO RECEIVE AN UPFRONT LICENSE FEE AND POTENTIAL RESEARCH, DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS FROM SHIRE​.SHIRE PLC - SHIRE RECEIVES EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP AND COMMERCIALIZE PRIM PROGRAM.  Full Article

Shire Says Granted EU marketing Authorization For ADYNOVI For Adults And Adolescents With Hemophilia A
Monday, 15 Jan 2018 

Jan 15 (Reuters) - Shire Plc ::SHIRE GRANTED EU MARKETING AUTHORIZATION FOR ADYNOVI [ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED] FOR ADULTS AND ADOLESCENTS WITH HEMOPHILIA A​.‍SHIRE IS NOW AUTHORIZED TO MARKET ADYNOVI IN 28 MEMBER STATES OF EUROPEAN UNION (EU), AS WELL AS IN ICELAND, LIECHTENSTEIN AND NORWAY​.  Full Article

Shire Says Xiidra Approved By Health Canada To Treat Signs And Symptoms Of Dry Eye Disease
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Shire Plc ::XIIDRA APPROVED BY HEALTH CANADA TO TREAT SIGNS AND SYMPTOMS OF DRY EYE DISEASE.XIIDRA WILL BE AVAILABLE FOR PATIENTS IN CANADA IN EARLY 2018..  Full Article

Shire Files For FDA Approval Of New Plasma Manufacturing Facility In Covington, Georgia
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Shire Plc ::SHIRE FILES FOR FDA APPROVAL OF A NEW PLASMA MANUFACTURING FACILITY IN COVINGTON, GEORGIA TO SUPPORT GROWING IMMUNOLOGY FRANCHISE.SHIRE PLC - ‍COMMERCIAL PRODUCTION EXPECTED TO BEGIN IN 2018​.SHIRE PLC - EXPECTS TO MAKE A SECOND SUBMISSION TO FDA IN 2018 FOR ITS ALBUMIN THERAPY.  Full Article

Shire Says ‍U.S. FDA Has Granted Marketing Clearance To myPKFiT
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Shire Plc ::‍U.S. FOOD AND DRUG ADMINISTRATION HAS GRANTED 510(K) MARKETING CLEARANCE TO MYPKFIT FOR ADVATE​.  Full Article

Shire Plc Appoints ‍John Miller As Interim CFO
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Shire PLC ::SHIRE PLC SAYS ‍JOHN MILLER TO SERVE AS INTERIM CFO WITH EFFECT FROM JAN 1, 2018 UNTIL THOMAS DITTRICH COMMENCES HIS EMPLOYMENT WITH CO - SEC FILING​.SAYS ‍MILLER ENTERED NEW LETTER AGREEMENT WITH CO PURSUANT TO WHICH HIS ANNUAL BASE SALARY TO INCREASE TO $765,000​ WHILE SERVING AS INTERIM CFO.  Full Article

Shire And Rani Therapeutics enter into collaboration to evaluate use of the Rani Pill technology
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Shire Plc ::SHIRE AND RANI THERAPEUTICS ENTER INTO COLLABORATION TO EVALUATE USE OF THE RANI PILL(TM) TECHNOLOGY FOR THE ORAL DELIVERY OF FACTOR THERAPY.- AS PART OF COLLABORATION, SHIRE HAS ALSO MADE AN EQUITY INVESTMENT INTO RANI THERAPEUTICS.SAYS SPECIFIC TERMS OF THIS DEAL WERE NOT DISCLOSED.  Full Article

Shire names Thomas Dittrich as CFO
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Shire Plc :Shire Plc <<>> says Thomas Dittrich will join company as chief financial officer​.Shire Plc <<>> says Thomas Dittrich will assume his role as CFO in early 2018 following a transition period from his current employer​.  Full Article

Omega Advisors dissolves share stake in Carrizo Oil & Gas, ups in Shire PLC
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Omega Advisors Inc::Omega Advisors Inc dissolves share stake in Carrizo Oil & Gas Inc - SEC Filing‍​.Omega Advisors Inc raises share stake in Shire PLC by about 31 percent to 653,977 sponsored ADRs.Omega Advisors Inc - Change in holdings are as of Sept 30, 2017 and compared with the previous quarter ended as of June 30, 2017.  Full Article

Shire says CHMP recommends EU marketing authorization for ADYNOVI [Antihemophilic Factor (Recombinant), PEGylated]
Monday, 13 Nov 2017 

Nov 13 (Reuters) - SHIRE PLC ::CHMP RECOMMENDS EU MARKETING AUTHORIZATION FOR ADYNOVI [antihemophilic factor (recombinant), pegylated] FOR ADULTS AND ADOLESCENTS WITH HEMOPHILIA A​.  Full Article

BRIEF-Shire Announces FDA Acceptance Of sBLA For Cinryze For Pediatric Hereditary Angioedema Use

* SHIRE ANNOUNCES FDA ACCEPTANCE OF SBLA FOR CINRYZE® FOR PEDIATRIC HEREDITARY ANGIOEDEMA USE